2024 Current Fiscal Year Report: Advisory Council on Blood Stem Cell

Transplantation	•		Council on Blood Stem
1. Department or Agency 2.			. Fiscal Year
Department of Health and Human 2 Services		024	
3. Committee or Subcommittee		b. GSA committee No.	
Advisory Council on Blood Stem Cell		3	1442
4. Is this New Dur Fiscal Year?	ing 5. Current 6. Charter Re	Expected newal Date	7. Expected Term Date
No	02/19/2023 02/	/19/2025	
8a. Was Terminat FiscalYear?	ed During ⁸ b. Spe Termina Authori	ation	8c. Actual Term Date
No			
9. Agency Recommendation FiscalYear	for Next	gislation Terminate?	10b. Legislation Pending?
Continue	Not App	licable	Not Applicable
11. Establishmen	t Authority Statuto	ory (Congres	s Created)
12. Specific Establishment Authority	13. Effective Date	14. Commitee Type	14c. Presidential?
42 U.S.C. 274k	12/20/2005	Continuing	No
Board	Committee Non	Scientific Pro	gram Advisory
Number of	lo Reports for his FiscalYear		
17a. 0 17b. Closed 0 17c. Partially Closed 0 Other Activities 0 17d. Total 0 Open			
Meetings and Dat No Meetings	es		

Current Next

	FY	FY
18a(1). Personnel Pmts to Non-Federal Members	\$0.0	00\$0.00
18a(2). Personnel Pmts to		
Federal Members	\$0.	00\$0.00
18a(3). Personnel Pmts to	\$0.0	00\$0.00
Federal Staff		
18a(4). Personnel Pmts to	\$0	00\$0.00
Non-Member Consultants	ψ0.	οοφο.οο
18b(1). Travel and Per Diem to	\$0.0	00\$0.00
Non-Federal Members	ψ0.	υψυ.υυ
18b(2). Travel and Per Diem to	\$0.0	00\$0.00
Federal Members	ψ0.	υψυ.υυ
18b(3). Travel and Per Diem to Federal Staff	\$0.0	00\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.	00\$0.00
18c. Other(rents,user charges, graphics, printing, mail, etc.)	\$0.	00\$0.00
18d. Total	ድር	00\$0.00
	Ф О.	00.00
19. Federal Staff Support Years (FTE)	0.0	00.00

20a. How does the Committee accomplish its purpose?

The ACBSCT was established to advise the Secretary of HHS on matters related to the activities of the C.W. Bill Young Cell Transplantation and the National Cord Blood Inventory Programs. The ACBSCT provides a consolidated, comprehensive source of expert, unbiased analysis and recommendations to the Secretary on the latest advances in the science of blood stem cell transplantation, including cord blood.

20b. How does the Committee balance its

membership?

The Council is composed of up to 15 voting members representing marrow donor and transplant centers; cord blood banks; birthing hospitals; transplant recipients; persons waiting for transplants; family members of recipients; and members of the general public. The Council has 4 ex-officio, non-voting members.

20c. How frequent and relevant are the Committee Meetings?

The Advisory Council shall convene at least two times each calendar year.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

This expertise is not available within HHS.

20e. Why is it necessary to close and/or partially closed committee meetings? N/A

21. Remarks

Max number of members changed from 25 to 19 in alignment with current charter (15 members and 4 ex-officios). Sridhar Basavaraju's term end date changed to 9/30/2023.

Designated Federal Officer

Shelley Grant Branch Chief, BSCTB, Division of Transplantation, Health Systems Bureau

Committee Members	Start	End	Occupation	Member Designation
Barker, Juliet	08/12/2022	11/05/2024	Memorial Sloan-Kettering Cancer Center	Special Government Employee (SGE) Member
Berkey, Ann	12/04/2022	12/03/2024	CEO, Berkey Group	Special Government Employee (SGE) Member

DiFronzo, Nancy	01/01/2017	01/01/2024	National Institutes of Health	Ex Officio Member Special
Finney, Marcie	08/12/2022	11/05/2024	Cleveland Cord Blood Center	Government Employee (SGE) Member
Grogl, Max	09/02/2022	09/01/2025	Department of Defense - Navy	Ex Officio Member
Holloman, Frank	01/01/2017	01/01/2024	Health Resources and Services Administration	Ex Officio Member
Jacob, Eapen	12/04/2022	12/03/2024	Medical Director, Human Cellular Therapy Laboratory at Mayo Clinic	Special Government Employee (SGE) Member
Khuu, Hanh	09/02/2022	09/01/2025	Food and Drug Administration	Ex Officio Member
Levine, John	08/12/2022	11/05/2024	Director, Blood and Marrow Transplant Clinical Research	Special Government Employee (SGE) Member
Majhail, Navneet	08/12/2022	11/05/2024	Sarah Cannon Transplant and Cellular Therapy Network	Special Government Employee (SGE) Member
Maziarz, Richard	12/04/2022	12/03/2024	Clinical Researcher	Special Government Employee (SGE) Member
Milano, Filippo	08/12/2022	11/05/2024	Director, Cord Blood Transplantation Program	Special Government Employee (SGE) Member

Number of Committee Members Listed: 12

Narrative Description

HHS has a vital role in safeguarding and promoting public health by overseeing the operation of the C.W. Bill Young Transplantation Program and the National Cord Blood Inventory. The principal purpose of these programs is to make blood stem cells from adult donors and cord blood units available for patients who need a transplant to treat life-threatening conditions, such as leukemia, and who lack a suitably matched relative who can be the donor.

What are the most significant program outcomes associated with this committee?

	Checked if Applies
Improvements to health or safety	\checkmark
Trust in government	\checkmark
Major policy changes	\checkmark
Advance in scientific research	\checkmark
Effective grant making	
Improved service delivery	\checkmark
Increased customer satisfaction	\checkmark
Implementation of laws or regulatory	1
requirements	ξ
Other	

Outcome Comments

N/A

What are the cost savings associated with this committee?

	Checked if Applies
None	\checkmark
Unable to Determine	
Under \$100,000	
\$100,000 - \$500,000	
\$500,001 - \$1,000,000	
\$1,000,001 - \$5,000,000	
\$5,000,001 - \$10,000,000	
Over \$10,000,000	
Cost Savings Other	

Cost Savings Comments

While the ACBSCT's recommendations have focused on improvements to patient care through blood stem cell transplant and efficiency in the system, direct cost savings for the government have not been measured.

What is the approximate <u>Number</u> of recommendations produced by this committee for the life of the committee?

Number of Recommendations Comments

No recommendations were made in FY 2023.

What is the approximate <u>Percentage</u> of these recommendations that have been or will be <u>Fully</u> implemented by the agency?

48%

% of Recommendations Fully Implemented Comments

The Program and the community are engaged in discussions about the implementation of all recommendations.

What is the approximate <u>Percentage</u> of these recommendations that have been or will be <u>Partially</u> implemented by the agency? 52%

% of Recommendations Partially Implemented Comments

The Program and the community are engaged in discussions about the implementation of all recommendations.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes 🗹 No 🗌 Not Applicable 🗌

Agency Feedback Comments

The Secretary of HHS acknowledges receipt of any recommendations. The public can obtain information on agency feedback at the ACBSCT website: https://bloodcell.transplant.hrsa.gov/about/advisory_council/index.html

What other actions has the agency taken as a result of the committee's advice or recommendation?

Reorganized Priorities	✓
Reallocated resources	
Issued new regulation	
Proposed legislation	
Approved grants or other payments	
Other	

Action Comments

N/A

Is the Committee engaged in the review of applications for grants? No

Grant Review Comments N/A

How is access provided to the information for the Committee's documentation?

	Checked if Applies
Contact DFO	\checkmark
Online Agency Web Site	\checkmark
Online Committee Web Site	\checkmark
Online GSA FACA Web Site	\checkmark
Publications	
Other	

Access Comments

N/A